COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives $16.29 Consensus PT from Brokerages

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) has been assigned an average rating of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $16.2857.

Several equities research analysts have recently commented on CMPS shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of COMPASS Pathways in a research report on Friday, August 1st. HC Wainwright reduced their price objective on shares of COMPASS Pathways from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, August 4th. Evercore ISI restated an “in-line” rating and set a $6.00 price objective (down from $11.00) on shares of COMPASS Pathways in a research note on Monday, June 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $12.00 price objective on shares of COMPASS Pathways in a research note on Tuesday, May 27th.

COMPASS Pathways Stock Performance

Shares of CMPS opened at $5.04 on Friday. The stock has a market capitalization of $483.54 million, a P/E ratio of -2.74 and a beta of 2.17. The company has a quick ratio of 8.82, a current ratio of 8.82 and a debt-to-equity ratio of 0.16. The firm has a fifty day simple moving average of $4.57 and a two-hundred day simple moving average of $3.95. COMPASS Pathways has a twelve month low of $2.25 and a twelve month high of $7.09.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Thursday, July 31st. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). On average, research analysts anticipate that COMPASS Pathways will post -2.33 EPS for the current year.

Institutional Trading of COMPASS Pathways

Institutional investors have recently made changes to their positions in the stock. Woodline Partners LP boosted its holdings in shares of COMPASS Pathways by 279.9% during the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock valued at $5,019,000 after acquiring an additional 1,292,927 shares during the last quarter. Polar Asset Management Partners Inc. purchased a new stake in shares of COMPASS Pathways during the 1st quarter valued at about $657,000. Jane Street Group LLC boosted its holdings in shares of COMPASS Pathways by 72.7% during the 4th quarter. Jane Street Group LLC now owns 51,815 shares of the company’s stock valued at $196,000 after acquiring an additional 21,815 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of COMPASS Pathways by 93.6% during the 1st quarter. GAMMA Investing LLC now owns 10,349 shares of the company’s stock valued at $30,000 after acquiring an additional 5,003 shares during the last quarter. Finally, ARK Investment Management LLC boosted its holdings in shares of COMPASS Pathways by 4.0% during the 1st quarter. ARK Investment Management LLC now owns 1,804,803 shares of the company’s stock valued at $5,162,000 after acquiring an additional 68,601 shares during the last quarter. Hedge funds and other institutional investors own 46.19% of the company’s stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.